JP2015512923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512923A5 JP2015512923A5 JP2015504946A JP2015504946A JP2015512923A5 JP 2015512923 A5 JP2015512923 A5 JP 2015512923A5 JP 2015504946 A JP2015504946 A JP 2015504946A JP 2015504946 A JP2015504946 A JP 2015504946A JP 2015512923 A5 JP2015512923 A5 JP 2015512923A5
- Authority
- JP
- Japan
- Prior art keywords
- cushing
- combination
- combination according
- syndrome
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 15
- 206010011652 Cushing's syndrome Diseases 0.000 claims description 10
- 206010035109 Pituitary-dependent Cushing's syndrome Diseases 0.000 claims description 10
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 229960005415 pasireotide Drugs 0.000 claims description 6
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 4
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 claims description 4
- 229960002700 Octreotide Drugs 0.000 claims description 4
- 108010016076 Octreotide Proteins 0.000 claims description 4
- 229960002437 lanreotide Drugs 0.000 claims description 4
- 108010021336 lanreotide Proteins 0.000 claims description 4
- -1 6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl Chemical group 0.000 claims description 3
- USUZGMWDZDXMDG-CYBMUJFWSA-N 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CC1 USUZGMWDZDXMDG-CYBMUJFWSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 claims 1
- JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 description 1
- INRNDPUMEATXKG-UHFFFAOYSA-N 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole Chemical compound N1=CN2CCCC2=C1 INRNDPUMEATXKG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261623117P | 2012-04-12 | 2012-04-12 | |
US61/623,117 | 2012-04-12 | ||
PCT/EP2013/057515 WO2013153129A1 (en) | 2012-04-12 | 2013-04-10 | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015512923A JP2015512923A (ja) | 2015-04-30 |
JP2015512923A5 true JP2015512923A5 (pt-PT) | 2016-05-19 |
JP6383352B2 JP6383352B2 (ja) | 2018-08-29 |
Family
ID=48289057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015504946A Active JP6383352B2 (ja) | 2012-04-12 | 2013-04-10 | ソマトスタチンアナログの11ベータ−水酸化酵素阻害剤との組合せ |
Country Status (12)
Country | Link |
---|---|
US (1) | US9333234B2 (pt-PT) |
EP (1) | EP2836228B1 (pt-PT) |
JP (1) | JP6383352B2 (pt-PT) |
KR (1) | KR102136214B1 (pt-PT) |
CN (1) | CN104321074B (pt-PT) |
AU (1) | AU2013246908B2 (pt-PT) |
BR (1) | BR112014025058B1 (pt-PT) |
CA (1) | CA2869442C (pt-PT) |
IN (1) | IN2014DN09240A (pt-PT) |
MX (1) | MX362533B (pt-PT) |
RU (1) | RU2663455C2 (pt-PT) |
WO (1) | WO2013153129A1 (pt-PT) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ601077A (en) * | 2010-01-14 | 2014-07-25 | Novartis Ag | Use of an adrenal hormone-modifying agent |
WO2016005880A1 (en) * | 2014-07-07 | 2016-01-14 | Novartis Ag | Pharmaceutical dosage forms |
WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
CA3011728A1 (en) | 2016-01-19 | 2017-07-27 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ509348A (en) * | 1998-07-30 | 2004-02-27 | Sod Conseils Rech Applic | Use of a somatostatin analogue Lanreotide |
MXPA03009048A (es) * | 2001-04-09 | 2004-02-12 | Univ Tulane | Agonistas de la somatostatina. |
GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
ES2472446T3 (es) * | 2009-11-30 | 2014-07-01 | Novartis Ag | Derivados de imidazol como inhibidores de aldosterona sintasa |
NZ601077A (en) * | 2010-01-14 | 2014-07-25 | Novartis Ag | Use of an adrenal hormone-modifying agent |
WO2013131879A1 (en) * | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
-
2013
- 2013-04-10 BR BR112014025058-8A patent/BR112014025058B1/pt active IP Right Grant
- 2013-04-10 CN CN201380027076.7A patent/CN104321074B/zh active Active
- 2013-04-10 MX MX2014012321A patent/MX362533B/es active IP Right Grant
- 2013-04-10 KR KR1020147031324A patent/KR102136214B1/ko active IP Right Grant
- 2013-04-10 AU AU2013246908A patent/AU2013246908B2/en active Active
- 2013-04-10 JP JP2015504946A patent/JP6383352B2/ja active Active
- 2013-04-10 EP EP13720275.0A patent/EP2836228B1/en active Active
- 2013-04-10 WO PCT/EP2013/057515 patent/WO2013153129A1/en active Application Filing
- 2013-04-10 US US14/391,416 patent/US9333234B2/en active Active
- 2013-04-10 RU RU2014145351A patent/RU2663455C2/ru active
- 2013-04-10 IN IN9240DEN2014 patent/IN2014DN09240A/en unknown
- 2013-04-10 CA CA2869442A patent/CA2869442C/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010270124A5 (pt-PT) | ||
JP2016530280A5 (pt-PT) | ||
JP2012255026A5 (pt-PT) | ||
JP2016508134A5 (pt-PT) | ||
JP2014509659A5 (pt-PT) | ||
JP2015512418A5 (pt-PT) | ||
AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
JP2011225596A5 (pt-PT) | ||
WO2009043448A3 (en) | Neuromedin u-25 and neuromedin s as therapeutic agents | |
JP2020521797A5 (pt-PT) | ||
RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
JP2016510326A5 (pt-PT) | ||
JP2017532343A5 (pt-PT) | ||
JP2016516016A5 (pt-PT) | ||
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
JP2015522018A5 (pt-PT) | ||
EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
JP2013543491A5 (pt-PT) | ||
JP2015512923A5 (pt-PT) | ||
JP2009500045A5 (pt-PT) | ||
JP2017501154A5 (pt-PT) | ||
JP2015516419A5 (pt-PT) | ||
JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
JP2013541583A5 (pt-PT) | ||
JP2015522603A5 (pt-PT) |